Epsilon M&A Deal Report - Biolix
Transaction Multiples for the Valuation of Private Companies
B2A (Biola) / Biolix
No EMAT :
112613
Announced Date :
18/02/2020
Type :
Acquisition of Majority Stake
Deal Value :
Yes
Acquirer :
B2A (Biola)
Target :
Biolix
Country :
France
Sector of activity :
- Laboratories > Pharmaceuticals & Cosmetics > Health, Pharmaceuticals & Biotechnology > Medical Diagnostic Laboratory
Business Description :
Founded in 1945, Biolix Delas owns and operates several medical laboratories in Alsace (Bas-Rhin) and Vosges.
Transaction multiples available
| EV/ Sales |
EV/ Gross Profit |
EV/ EBITDA |
EV/ EBIT |
Eq/ PBT |
P/E | Price to Book |
Specific multiple(s) |
|
|---|---|---|---|---|---|---|---|---|
| Historic | 
|
|
|
|
|
|
|
|
| Current |
Rating :
**
|
|
Multiple available |
| n.s. | Multiple calculated, but not significant |
Source: Epsilon Research / EMAT
Comparable Transactions
- Number of EMAT Reports / sub-sector « Medical Diagnostic Laboratory » = 50
| Date | Acquirer | Target | Country | Multiples | See details |
| 24/04/2023 | Private Group backed by Vivalto Partners | Laboratoires Delbert | France | * | 112600 |
| 20/12/2019 | Biolix | Analysis | France | *** | 112577 |
Source: Epsilon Research / EMAT
